Please check your internet connection and try again.
# Potassium Chloride
## Overview
Potassium chloride (KCl) is an electrolyte supplement used to prevent or treat hypokalemia. It is available in oral and intravenous formulations.
## Primary Indications
* Treatment and prevention of hypokalemia.
## Adult Dosing
* **Oral:**
* Prevention: 20 mEq (1.5 g) daily in 1-2 divided doses.
* Treatment: 40-100 mEq (3-7.5 g) daily in 2-4 divided doses. Maximum daily dose typically 200 mEq (15 g).
* **Intravenous (IV):**
* **Mild to moderate hypokalemia (serum K+ 2.5-3.5 mEq/L):** Up to 20 mEq per dose, infused over at least 2-3 hours.
* **Severe hypokalemia (serum K+ < 2.5 mEq/L):** May require higher doses, but typically limited to 10 mEq/hour infusion rate via a peripheral IV line to prevent phlebitis and cardiac arrhythmias. Higher rates (e.g., 20-40 mEq/hour) may be used in life-threatening situations via a central line with continuous cardiac monitoring. Maximum daily dose usually 200-400 mEq (15-30 g).
* **Concentration:** Typically diluted to a maximum of 40 mEq/L for peripheral infusions and 60-80 mEq/L for central infusions.
## Pediatric Dosing
* **Oral:** 1-2 mEq/kg/day in 2-4 divided doses, not to exceed adult maximums.
* **Intravenous (IV):**
* General: 0.5-1 mEq/kg/dose infused over 1-3 hours.
* Severe hypokalemia: May require higher doses and/or faster infusion rates with continuous cardiac monitoring, per local protocol. Maximum daily dose typically 12 mEq/kg/day or 300 mEq/day, whichever is less.
* Concentration: Maximum of 40 mEq/L for peripheral infusion.
## Dose Adjustments
* Renal impairment: Use with extreme caution; dosage reduction is often necessary. Monitor potassium levels closely.
## Contraindications
* Hyperkalemia.
* Conditions causing sustained high levels of potassium (e.g., severe renal impairment, untreated Addison's disease, extensive tissue breakdown).
* Certain gastrointestinal conditions (e.g., intestinal obstruction, peptic ulcer, esophageal compression) when using sustained-release oral formulations due to risk of ulceration.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal discomfort, flatulence.
* **Serious:** Hyperkalemia (manifesting as cardiac arrhythmias, ECG changes, muscle weakness, paralysis), phlebitis (with IV administration), gastrointestinal ulceration/perforation (with oral sustained-release).
## Key Drug Interactions
* **ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin:** Increased risk of hyperkalemia.
* **Aldosterone antagonists:** Increased risk of hyperkalemia.
* **Digoxin:** Hyperkalemia may increase the risk of digoxin toxicity. Hypokalemia may enhance digoxin toxicity.
* **Neuromuscular blocking agents:** May potentiate neuromuscular blockade.
## Monitoring
* Serum potassium levels (frequently, especially during IV administration or dose changes).
* Renal function (BUN, creatinine).
* ECG (especially with IV potassium or risk of hyperkalemia).
* Signs and symptoms of hypokalemia and hyperkalemia.
* Fluid and electrolyte balance.
## Clinical Pearls
* Oral liquid formulations and microencapsulated products are generally preferred over sustained-release tablets to reduce the risk of gastrointestinal irritation and ulceration.
* IV potassium is a vesicant and can cause severe phlebitis and tissue damage if infiltrated. Always dilute and infuse at recommended rates.
* Never administer IV potassium undiluted.
* Rapid IV infusion of potassium can be fatal.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
